Interval prolongation of etanercept in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis: a randomized controlled trial

Autor: J Ruwaard, MJ L’ Ami, EL Kneepkens, CLM Krieckaert, MT Nurmohamed, F Hooijberg, AWR van Kuijk, JC van Denderen, L Burgemeister, T Rispens, M Boers, GJ Wolbink

Publikováno v: Scandinavian journal of rheumatology. Informa Healthcare
Ruwaard, J, l’ Ami, M J, Kneepkens, E L, Krieckaert, C L M, Nurmohamed, M T, Hooijberg, F, van Kuijk, A W R, van Denderen, J C, Burgemeister, L, Rispens, T, Boers, M & Wolbink, G J 2022, ' Interval prolongation of etanercept in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis : a randomized controlled trial ', Scandinavian Journal of Rheumatology . https://doi.org/10.1080/03009742.2022.2028364
Scandinavian Journal of Rheumatology. Informa Healthcare

Objective: The majority of patients with a rheumatic disease treated with etanercept may be overexposed. Data regarding etanercept tapering are scarce, particularly in psoriatic arthritis (PsA) and ankylosing spondylitis (AS). We compared extending t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5ef1c12c8fadcb65cb3ab4762f6e5d61
https://doi.org/10.1080/03009742.2022.2028364

Interval prolongation of etanercept in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis: a randomized controlled trial.

Autor: Ruwaard J; Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, Amsterdam, The Netherlands., L' Ami MJ; Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, Amsterdam, The Netherlands., Kneepkens EL; Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, Amsterdam, The Netherlands., Krieckaert C; Department of Rheumatology, Amsterdam UMC | Vrije Universiteit, Amsterdam, The Netherlands., Nurmohamed MT; Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, Amsterdam, The Netherlands.; Department of Rheumatology, Amsterdam UMC | Vrije Universiteit, Amsterdam, The Netherlands., Hooijberg F; Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, Amsterdam, The Netherlands., van Kuijk A; Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, Amsterdam, The Netherlands., van Denderen JC; Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, Amsterdam, The Netherlands., Burgemeister L; Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, Amsterdam, The Netherlands., Rispens T; Department of Immunopathology, Sanquin Research and Landsteiner Laboratory Academic Medical Center, Amsterdam, The Netherlands., Boers M; Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, Amsterdam, The Netherlands.; Department of Rheumatology, Amsterdam UMC | Vrije Universiteit, Amsterdam, The Netherlands.; Department of Epidemiology and Data Science, Amsterdam UMC | Vrije Universiteit, Amsterdam, The Netherlands., Wolbink GJ; Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, Amsterdam, The Netherlands.; Department of Immunopathology, Sanquin Research and Landsteiner Laboratory Academic Medical Center, Amsterdam, The Netherlands.

Publikováno v: Scandinavian journal of rheumatology [Scand J Rheumatol] 2023 Mar; Vol. 52 (2), pp. 129-136. Date of Electronic Publication: 2022 Mar 02.

Preventability of unplanned readmissions within 30 days of discharge. A cross-sectional, single-center study.

Autor: van der Does AMB; Department of Clinical Pharmacy, OLVG, Amsterdam, The Netherlands., Kneepkens EL; Department of Clinical Pharmacy, OLVG, Amsterdam, The Netherlands., Uitvlugt EB; Department of Clinical Pharmacy, OLVG, Amsterdam, The Netherlands., Jansen SL; Department of Surgery, OLVG, Amsterdam, The Netherlands., Schilder L; Department of Internal medicine, OLVG, Amsterdam, The Netherlands., Tokmaji G; Department of Cardiology, OLVG, Amsterdam, The Netherlands., Wijers SC; Department of Internal medicine, OLVG, Amsterdam, The Netherlands., Radersma M; Department of Gastroenterology, OLVG, Amsterdam, The Netherlands., Heijnen JNM; Department of Neurology, OLVG, Amsterdam, The Netherlands., Teunissen PFA; Department of Internal medicine, OLVG, Amsterdam, The Netherlands., Hulshof PBJE; Department of Internal medicine, OLVG, Amsterdam, The Netherlands., Overvliet GM; Department of Psychiatry, OLVG, Amsterdam, The Netherlands., Siegert CEH; Department of Internal medicine, OLVG, Amsterdam, The Netherlands., Karapinar-Çarkit F; Department of Clinical Pharmacy, OLVG, Amsterdam, The Netherlands.

Publikováno v: PloS one [PLoS One] 2020 Apr 02; Vol. 15 (4), pp. e0229940. Date of Electronic Publication: 2020 Apr 02 (Print Publication: 2020).

Association between concomitant csDMARDs and clinical response to TNF inhibitors in overweight patients with axial spondyloarthritis.

Autor: Hernández-Breijo B; Immuno-Rheumatology Research Group, IdiPaz, University Hospital La Paz, Paseo de La Castellana 261, 28046, Madrid, Spain. borja.hernandez@idipaz.es.; Immunology, University Hospital La Paz, Madrid, Spain. borja.hernandez@idipaz.es., Plasencia-Rodríguez C; Immuno-Rheumatology Research Group, IdiPaz, University Hospital La Paz, Paseo de La Castellana 261, 28046, Madrid, Spain.; Rheumatology, University Hospital La Paz, Madrid, Spain., Navarro-Compán V; Immuno-Rheumatology Research Group, IdiPaz, University Hospital La Paz, Paseo de La Castellana 261, 28046, Madrid, Spain.; Rheumatology, University Hospital La Paz, Madrid, Spain., Martínez-Feito A; Immuno-Rheumatology Research Group, IdiPaz, University Hospital La Paz, Paseo de La Castellana 261, 28046, Madrid, Spain.; Immunology, University Hospital La Paz, Madrid, Spain., Jochems A; Immuno-Rheumatology Research Group, IdiPaz, University Hospital La Paz, Paseo de La Castellana 261, 28046, Madrid, Spain., Kneepkens EL; Rheumatology, READE, Amsterdam, Netherlands., Wolbink GJ; Rheumatology, READE, Amsterdam, Netherlands., Rispens T; Immunopathology, Sanquin, Amsterdam, Netherlands., Diego C; Immunology, University Hospital La Paz, Madrid, Spain., Pascual-Salcedo D; Immuno-Rheumatology Research Group, IdiPaz, University Hospital La Paz, Paseo de La Castellana 261, 28046, Madrid, Spain., Balsa A; Immuno-Rheumatology Research Group, IdiPaz, University Hospital La Paz, Paseo de La Castellana 261, 28046, Madrid, Spain.; Rheumatology, University Hospital La Paz, Madrid, Spain.

Publikováno v: Arthritis research & therapy [Arthritis Res Ther] 2019 Feb 20; Vol. 21 (1), pp. 66. Date of Electronic Publication: 2019 Feb 20.

Impact of Stopping Tumor Necrosis Factor Inhibitors on Rheumatoid Arthritis Patients' Burden of Disease.

Autor: Ghiti Moghadam M; Arthritis Centre Twente, University of Twente, and Medisch Spectrum Twente, Enschede, The Netherlands., Ten Klooster PM; Arthritis Centre Twente, University of Twente, and Medisch Spectrum Twente, Enschede, The Netherlands., Vonkeman HE; Arthritis Centre Twente, University of Twente, and Medisch Spectrum Twente, Enschede, The Netherlands., Kneepkens EL; Reade, Amsterdam, The Netherlands., Klaasen R; Meander Medical Centre, Amersfoort, The Netherlands., Stolk JN; Gelderse Vallei Hospital, Ede, The Netherlands., Tchetverikov I; Albert Schweitzer Hospital, Dordrecht, The Netherlands., Vreugdenhil SA; St. Antonius Hospital, Nieuwegein, The Netherlands., van Woerkom JM; Gelre Hospitals, Apeldoorn, The Netherlands., Goekoop-Ruiterman YPM; Haga Hospital, The Hague, The Netherlands., Landewé RBM; Academic Medical Center, Amsterdam, The Netherlands., van Riel PLCM; Radboud University Medical Center, Nijmegen, The Netherlands., van de Laar MAFJ; Arthritis Centre Twente, University of Twente, and Medisch Spectrum Twente, Enschede, The Netherlands., Jansen TL; VieCuri Medical Center, Venlo, The Netherlands.

Publikováno v: Arthritis care & research [Arthritis Care Res (Hoboken)] 2018 Apr; Vol. 70 (4), pp. 516-524.